Kermanshah University of Medical Sciences Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2007
NCT00527540
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Kermanshah University of Medical Sciences | Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. | Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran | Soudabeh Eshghi ali

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6